Author:
Michael Fausta,Mirambo Mariam M.,Lyimo Dafrossa,Salehe Abdul,Kyesi Furaha,Msanga Delfina R.,Mahamba Dina,Nyawale Helmut,Kwiyolecha Elizabeth,Okamo Bernard,Mwanyika Paul J.,Maghina Victoria,Bendera Elice,Salehe Mohammed,Hokororo Adolfine,Mwipopo Ernestina,Khamis Asha C.,Nyaki Honest,Magodi Richard,Mujuni Delphius,Konje Eveline T.,Katembo Betina,Wilillo Ritha,Mshana Stephen E.
Abstract
AbstractThe study aims to determine Rotavirus genotypes between 2013 and 2018 during implementation of ROTARIX vaccine in Tanzania. The analysis of surveillance data obtained between 2013 and 2018 was done to determine circulating genotypes after introduction of Rotarix vaccine. From 2013 to 2018, a total of 10,557 samples were collected and screened for Rotavirus using an enzyme immunoassay. A significant decrease in Rotavirus positivity (29.3% to 17.8%) from 2013 to 2018 (OR 0.830, 95% CI 0.803–0.857, P < 0.001) was observed. A total of 766 randomly selected Rotavirus positive samples were genotyped. Between 2013 and 2018, a total of 18 Rotavirus genotypes were detected with G1P [8] being the most prevalent. The G1P [8] strain was found to decrease from 72.3% in 2015 to 13.5% in 2018 while the G9P [4] strain increased from 1 to 67.7% in the same years. G2P [4] was found to decrease from 59.7% in 2013 to 6.8% in 2018 while G3P [6] decreased from 11.2% in 2014 to 4.1% in 2018. The data has clearly demonstrated that ROTARIX vaccine has provided protection to varieties of the wild-type Rotavirus strains. Continuous surveillance is needed to monitor the circulation of Rotavirus strains during this era of vaccine implementation.
Publisher
Springer Science and Business Media LLC